MARKET

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6550
+0.0430
+7.03%
Closed 16:57 09/25 EDT
OPEN
0.6190
PREV CLOSE
0.6120
HIGH
0.6700
LOW
0.5914
VOLUME
504.38K
TURNOVER
--
52 WEEK HIGH
1.705
52 WEEK LOW
0.4195
MARKET CAP
34.89M
P/E (TTM)
-0.8690
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Seelos Therapeutics Announces Sponsored Research Agreement With Duke University For Gene Therapy Studies Of SLS-004 In Parkinson's Disease
NEW YORK, Sept. 23, 2020 /PRNewswire/ --Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare
Benzinga · 4d ago
Seelos Therapeutics Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinson's Disease
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the signing of a Sponsored Research Agreement (SRA) with Duke University to use the MPTP-induced Parkinson
PR Newswire · 4d ago
Seelos Announces Issuance Of New Patent And Additional Notice Of Allowance In Japan For Intranasal Racemic Ketamine (SLS-002)
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare
Benzinga · 09/14 13:02
Seelos Announces Issuance of a New Patent and an Additional Notice of Allowance in Japan for Intranasal Racemic Ketamine (SLS-002)
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6722453) covering
PR Newswire · 09/14 13:00
Seelos nabs additional US patent for SLS-005
Seelos Therapeutics ([[SEEL]] -0.05%) receives Notice of Allowance from the USPTO for method of using trehalose (SLS-005) to treat several neurodegenerative conditions.Recently, the company announced European Orphan Drug tag for SLS-005 for
Seekingalpha · 09/10 14:38
Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for
PR Newswire · 09/10 13:00
Why Seelos Therapeutics' Stock Is Trading Lower Today
Seelos Therapeutics (NASDAQ: SEEL) shares are trading lower on Friday after the company announced an 8.865 million shares common stock offering at 79 cents per share.
Benzinga · 09/04 14:01
Seelos under pressure after pricing stock offering
Seelos Therapeutics (SEEL) has priced its direct offering of ~8.9M common shares at $0.79 per share yielding gross proceeds of ~$7M.Institutional investors will receive five-year warrants to purchase up to
Seekingalpha · 09/04 13:18
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SEEL. Analyze the recent business situations of Seelos Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SEEL stock price target is 8.00 with a high estimate of 12.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 50
Institutional Holdings: 4.66M
% Owned: 8.75%
Shares Outstanding: 53.27M
TypeInstitutionsShares
Increased
5
207.51K
New
19
-116.17K
Decreased
5
849.55K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.88%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/President/Chief Executive Officer/Chief Financial Officer/Director
Raj Mehra
Chief Scientific Officer
Warren Wasiewski
Director
Judith Dunn
Director
Brian Lian
Director
Daniel O'Connor
Director
Richard Pascoe
Independent Director
Wendell Wierenga
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SEEL
Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Seelos Therapeutics Inc stock information, including NASDAQ:SEEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SEEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SEEL stock methods without spending real money on the virtual paper trading platform.